• Something wrong with this record ?

PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study

S. Svobodova, M. Karlikova, O. Topolcan, L. Pecen, M. Pestova, O. Kott, V. Treska, D. Slouka, R. Kucera,

. 2018 ; 32 (6) : 1551-1554.

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19012234

AIM: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. MATERIALS AND METHODS: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). RESULTS: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. CONCLUSION: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012234
003      
CZ-PrNML
005      
20190412092453.0
007      
ta
008      
190405s2018 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/invivo.11413 $2 doi
035    __
$a (PubMed)30348715
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Svobodova, Sarka $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic. Third Internal Medicine Department and First Medical Faculty, Charles University, Prague, Czech Republic.
245    10
$a PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study / $c S. Svobodova, M. Karlikova, O. Topolcan, L. Pecen, M. Pestova, O. Kott, V. Treska, D. Slouka, R. Kucera,
520    9_
$a AIM: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. MATERIALS AND METHODS: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). RESULTS: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. CONCLUSION: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a nádorové biomarkery $x krev $7 D014408
650    _2
$a hepatocelulární karcinom $x krev $x genetika $x patologie $7 D006528
650    _2
$a diferenciální diagnóza $7 D003937
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a jaterní cirhóza $x krev $x genetika $x patologie $7 D008103
650    _2
$a nádory jater $x krev $x genetika $x patologie $7 D008113
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a pilotní projekty $7 D010865
650    _2
$a proteinové prekurzory $x krev $x genetika $7 D011498
650    _2
$a protrombin $x genetika $7 D011516
655    _2
$a časopisecké články $7 D016428
700    1_
$a Karlikova, Marie $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
700    1_
$a Topolcan, Ondrej $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
700    1_
$a Pecen, Ladislav $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
700    1_
$a Pestova, Martina $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
700    1_
$a Kott, Otto $u Faculty of Health Care Studies, University of West Bohemia, Pilsen, Czech Republic.
700    1_
$a Treska, Vladislav $u Department of Surgery, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
700    1_
$a Slouka, David $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic.
700    1_
$a Kucera, Radek $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Czech Republic kucerar@fnplzen.cz.
773    0_
$w MED00175831 $t In vivo (Athens, Greece) $x 1791-7549 $g Roč. 32, č. 6 (2018), s. 1551-1554
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30348715 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190412092512 $b ABA008
999    __
$a ok $b bmc $g 1391544 $s 1050539
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 32 $c 6 $d 1551-1554 $i 1791-7549 $m In Vivo $n In Vivo $x MED00175831
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Archiving options